D. Ferraro

发表

Cyclin E1 protein is stabilized in BRCA1 mutated breast cancers leading to synergy between CDK2 and PARP inhibitors

D. Etemadmoghadam, D. Bowtell, V. Serra, 2020, bioRxiv.

SMALL CELL LuNg CANCER uPDATE

M. Millward, D. Ferraro, 2013 .

Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial

V. Gebski, N. Pavlakis, V. Ganju, 2016, British Journal of Cancer.

Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin)-treated patients with metastatic pancreatic cancer: The randomized phase II PAN1 study.

V. Gebski, J. Mackey, D. Goldstein, 2014 .

Discussing and prescribing expensive unfunded anticancer drugs in Australia

M. Stockler, L. Mileshkin, A. Martin, 2017, ESMO Open.

perspective on the role of targeted therapies in gastroesophageal cancer

S. Fox, N. Tebbutt, D. Ferraro, 2011 .

Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy

J. Zalcberg, D. Ferraro, 2014, Therapeutic advances in medical oncology.

1202 Discussing and prescribing expensive unfunded anticancer drugs in Australia

M. Stockler, L. Mileshkin, A. Martin, 2015 .

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition

D. Etemadmoghadam, D. Bowtell, V. Serra, 2021, NPJ breast cancer.

Gemcitabine‐based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score‐matched cohort study

U. Boggi, N. Jamieson, C. Bassi, 2020, The British journal of surgery.

TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

V. Gebski, D. Goldstein, J. Zalcberg, 2016, Cancer Chemotherapy and Pharmacology.

Patient versus clinician preferences for chemotherapy in non-small-cell lung cancer

M. Stockler, P. Blinman, D. Ferraro, 2013 .